IONS · Company research
Ionis Pharmaceuticals, Inc. Common Stock (IONS): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
26records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| IONS Nov 2026 50.000 call (IONS261120C00050000) Stock Price, News, Quote & History - Yahoo! Finance Canada | IONS Nov 2026 50.000 call (IONS261120C00050000) Stock Price, News, Quote & History Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Oct 17, 2026 | neutral | 0 | 0.6 |
| IONS Nov 2026 70.000 call (IONS261120C00070000) Stock Historical Prices & Data - Yahoo! Finance Canada | IONS Nov 2026 70.000 call (IONS261120C00070000) Stock Historical Prices & Data Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Oct 17, 2026 | neutral | 0 | 0.6 |
| IONS Nov 2026 47.500 call (IONS261120C00047500) Stock Price, News, Quote & History - Yahoo! Finance Canada | IONS Nov 2026 47.500 call (IONS261120C00047500) Stock Price, News, Quote & History Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Oct 17, 2026 | neutral | 0 | 0.6 |
| IONS Nov 2026 50.000 put (IONS261120P00050000) Stock Price, News, Quote & History - Yahoo! Finance Canada | IONS Nov 2026 50.000 put (IONS261120P00050000) Stock Price, News, Quote & History Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Oct 17, 2026 | neutral | 0 | 0.6 |
| IONS Nov 2026 37.500 put (IONS261120P00037500) Interactive Stock Chart - Yahoo Finance - Yahoo! Finance Canada | IONS Nov 2026 37.500 put (IONS261120P00037500) Interactive Stock Chart - Yahoo Finance Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Oct 17, 2026 | neutral | 0 | 0.6 |
| Officer Shannon Devers proposes selling 1,357 shares of Ionis Pharmaceuticals (IONS). - Stock Titan | Officer Shannon Devers proposes selling 1,357 shares of Ionis Pharmaceuticals (IONS). Stock Titan | View source ↗ | Stock Titan | Oct 16, 2026 | neutral | 0 | 0.6 |
| Lobbying Update: $150,000 of IONIS PHARMACEUTICALS INC. lobbying was just disclosed - Quiver Quantitative | Lobbying Update: $150,000 of IONIS PHARMACEUTICALS INC. lobbying was just disclosed Quiver Quantitative | View source ↗ | Quiver Quantitative | Oct 15, 2026 | neutral | 0 | 0.6 |
| IONS Apr 2027 62.500 call (IONS270416C00062500) Stock Price, News, Quote & History - Yahoo! Finance Canada | IONS Apr 2027 62.500 call (IONS270416C00062500) Stock Price, News, Quote & History Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Oct 15, 2026 | neutral | 0 | 0.6 |
| NVS, IONS, AMGN Stocks Drop After-Hours — What’s Driving The Selloff? - Stocktwits | NVS, IONS, AMGN Stocks Drop After-Hours — What’s Driving The Selloff? Stocktwits | View source ↗ | Stocktwits | Oct 9, 2026 | neutral | 0 | 0.6 |
| Ionis Pharmaceuticals (IONS) After The Pullback Is The Undervalued Narrative Still Intact - Yahoo Finance | Ionis Pharmaceuticals (IONS) After The Pullback Is The Undervalued Narrative Still Intact Yahoo Finance | View source ↗ | Yahoo Finance | Oct 9, 2026 | neutral | 0 | 0.6 |
| BBIO Stock Surges 16% As AstraZeneca-Ionis Heart Drug Trial Misses Goal — BofA Calls Failure ‘A Big Surprise’ - Stocktwits | BBIO Stock Surges 16% As AstraZeneca-Ionis Heart Drug Trial Misses Goal — BofA Calls Failure ‘A Big Surprise’ Stocktwits | View source ↗ | Stocktwits | Oct 9, 2026 | neutral | 0 | 0.6 |
| Ionis Pharmaceuticals (IONS) Stock Could Still Trade At A Premium Despite A 46% Slump - Yahoo Finance | Ionis Pharmaceuticals (IONS) Stock Could Still Trade At A Premium Despite A 46% Slump Yahoo Finance | View source ↗ | Yahoo Finance | Oct 9, 2026 | neutral | 0 | 0.6 |
| Is Ionis Pharmaceuticals (IONS) Stock Fully Valued After A 45% Fall? - Simply Wall Street | Is Ionis Pharmaceuticals (IONS) Stock Fully Valued After A 45% Fall? Simply Wall Street | View source ↗ | Simply Wall Street | Oct 8, 2026 | neutral | 0 | 0.6 |
| NVS Wins FDA Nod for Label Expansion of Immunology Drug Rhapsido | Novartis received FDA approval for Rhapsido (remibrutinib) for symptomatic dermographism (SD), making it the only prescription treatment approved for both CSU and SD, the two most common forms of chronic hives. The approval was supported by phase III RemIND trial data showing 29.3% complete hive resolution at week 12 versus 14% for placebo. The company is also evaluating remibrutinib in multiple sclerosis, hidradenitis suppurativa, and food allergy. However, Novartis faces pipeline setbacks with failed trials for pelacarsen and del-desiran, and generic competition pressuring blockbuster drugs. | View source ↗ | Zacks Investment Research | Oct 8, 2026 | bullish | 0.75 | 1 |
| NVS Wins FDA Nod for Label Expansion of Immunology Drug Rhapsido | Novartis received FDA approval for Rhapsido (remibrutinib) for symptomatic dermographism (SD), making it the only prescription treatment approved for both CSU and SD, the two most common forms of chronic hives. The approval was supported by phase III RemIND trial data showing 29.3% complete hive resolution at week 12 versus 14% for placebo. The company is also evaluating remibrutinib in multiple sclerosis, hidradenitis suppurativa, and food allergy. However, Novartis faces pipeline setbacks with failed trials for pelacarsen and del-desiran, and generic competition pressuring blockbuster drugs. | View source ↗ | Zacks Investment Research | Oct 8, 2026 | bullish | 0.75 | 1 |
| NVS Wins FDA Nod for Label Expansion of Immunology Drug Rhapsido | Novartis received FDA approval for Rhapsido (remibrutinib) for symptomatic dermographism (SD), making it the only prescription treatment approved for both CSU and SD, the two most common forms of chronic hives. The approval was supported by phase III RemIND trial data showing 29.3% complete hive resolution at week 12 versus 14% for placebo. The company is also evaluating remibrutinib in multiple sclerosis, hidradenitis suppurativa, and food allergy. However, Novartis faces pipeline setbacks with failed trials for pelacarsen and del-desiran, and generic competition pressuring blockbuster drugs. | View source ↗ | Zacks Investment Research | Oct 8, 2026 | bullish | 0.75 | 1 |
| IONS Stock Jumps 4% After-Hours — Goldman Sachs Lifts Price Target On Tryngolza Approval - Stocktwits | IONS Stock Jumps 4% After-Hours — Goldman Sachs Lifts Price Target On Tryngolza Approval Stocktwits | View source ↗ | Stocktwits | Oct 7, 2026 | neutral | 0 | 0.6 |
| Novartis Strengthens RNA Therapeutics Pipeline With $7.8B Abogen Deal | Novartis entered into a licensing agreement with Abogen Biosciences to acquire exclusive worldwide rights to ABO2203, an mRNA-encoded T-cell engager for autoimmune diseases. The deal includes a $575 million upfront payment and up to $7.2 billion in milestone payments. This move aims to strengthen Novartis' immunology pipeline following recent clinical setbacks in pelacarsen and del-desiran programs. | View source ↗ | Zacks Investment Research | Oct 5, 2026 | neutral | 0 | 1 |
| Royalty Pharma Owns a Piece of 16 Blockbuster Drugs -- Is the Stock a Buy? | Royalty Pharma (RPRX) offers investors diversified exposure to blockbuster drugs through a unique royalty-based investment model. With strong returns on invested capital (14.9% average ROIC), ownership in 16 blockbuster drugs, and analyst forecasts suggesting significant multiple expansion potential, the stock appears undervalued despite a 50% year-to-date surge. However, risks include share dilution and increasing competition in the pharma royalty space. | View source ↗ | The Motley Fool | Oct 1, 2026 | bullish | 0.2 | 1 |
| Royalty Pharma Owns a Piece of 16 Blockbuster Drugs -- Is the Stock a Buy? | Royalty Pharma (RPRX) offers investors diversified exposure to blockbuster drugs through a unique royalty-based investment model. With strong returns on invested capital (14.9% average ROIC), ownership in 16 blockbuster drugs, and analyst forecasts suggesting significant multiple expansion potential, the stock appears undervalued despite a 50% year-to-date surge. However, risks include share dilution and increasing competition in the pharma royalty space. | View source ↗ | The Motley Fool | Oct 1, 2026 | bullish | 0.2 | 1 |
| Ionis Pharmaceuticals (IONS) Stock Looks Pricey On Its 45% YTD Slide - Yahoo Finance | Ionis Pharmaceuticals (IONS) Stock Looks Pricey On Its 45% YTD Slide Yahoo Finance | View source ↗ | Yahoo Finance | Sep 24, 2026 | neutral | 0 | 0.6 |
| Ionis (IONS) Stock Looks Fully Valued As A Phase 3 Trial Miss Lands - Simply Wall Street | Ionis (IONS) Stock Looks Fully Valued As A Phase 3 Trial Miss Lands Simply Wall Street | View source ↗ | Simply Wall Street | Sep 18, 2026 | neutral | 0 | 0.6 |
| Cathie Wood Is Loading Up on Ionis Pharmaceuticals (IONS) Stock. Here's the Bet She's Making. - The Motley Fool | Cathie Wood Is Loading Up on Ionis Pharmaceuticals (IONS) Stock. Here's the Bet She's Making. The Motley Fool | View source ↗ | The Motley Fool | Sep 9, 2026 | neutral | 0 | 0.6 |
| Could Ionis Pharmaceuticals (IONS) Stock Become a Biotech Powerhouse as its Commercial Pipeline Takes Off? - Yahoo Finance | Could Ionis Pharmaceuticals (IONS) Stock Become a Biotech Powerhouse as its Commercial Pipeline Takes Off? Yahoo Finance | View source ↗ | Yahoo Finance | Aug 28, 2026 | neutral | 0 | 0.6 |
| Ionis (IONS) Stock Looks Like A Bargain On Value But Full On Sales - Yahoo Finance | Ionis (IONS) Stock Looks Like A Bargain On Value But Full On Sales Yahoo Finance | View source ↗ | Yahoo Finance | Aug 16, 2026 | neutral | 0 | 0.6 |
| Ionis Pharmaceuticals (IONS) Stock Slips As Revenue Drops And Losses Return - Simply Wall Street | Ionis Pharmaceuticals (IONS) Stock Slips As Revenue Drops And Losses Return Simply Wall Street | View source ↗ | Simply Wall Street | Jul 30, 2026 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.